Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
2.
Acta Oncol ; 52(4): 703-10, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23421926

RESUMO

UNLABELLED: During the past decade planning of adjuvant radiotherapy (RT) of early breast cancer has changed from two-dimensional (2D) to 3D conformal techniques. In the planning computerised tomography (CT) scan both the targets for RT and the organs at risk (OARs) are visualised, enabling an increased focus on target dose coverage and homogeneity with only minimal dose to the OARs. To ensure uniform RT in the national prospective trials of the Danish Breast Cancer Cooperative Group (DBCG), a national consensus for the delineation of clinical target volumes (CTVs) and OARs was required. MATERIAL AND METHODS: A CT scan of a breast cancer patient after surgical breast conservation and axillary lymph node (LN) dissection was used for delineation. During multiple dummy-runs seven experienced radiation oncologists contoured all CTVs and OARs of interest in adjuvant breast RT. Two meetings were held in the DBCG Radiotherapy Committee to discuss the contouring and to approve a final consensus. The Dice similarity coefficient (DSC) was used to evaluate the delineation agreement before and after the consensus. RESULTS: The consensus delineations of CTVs and OARs are available online and a table is presented with a contouring description of the individual volumes. The consensus provides recommendations for target delineation in a standard patient both in case of breast conservation or mastectomy. Before the consensus, the average value of the DSC was modest for most volumes, but high for the breast CTV and the heart. After the consensus, the DSC increased for all volumes. CONCLUSION: The DBCG has provided the first national guidelines and a contouring atlas of CTVs and OARs definition for RT of early breast cancer. The DSC is a useful tool in quantifying the effect of the introduction of guidelines indicating improved inter-delineator agreement. This consensus will be used by the DBCG in our prospective trials.


Assuntos
Neoplasias da Mama/patologia , Neoplasias da Mama/radioterapia , Órgãos em Risco/patologia , Planejamento da Radioterapia Assistida por Computador/métodos , Atlas como Assunto , Neoplasias da Mama/cirurgia , Dinamarca , Feminino , Humanos , Mastectomia Segmentar/legislação & jurisprudência , Mastectomia Segmentar/estatística & dados numéricos , Pessoa de Meia-Idade , Tamanho do Órgão/fisiologia , Órgãos em Risco/efeitos da radiação , Guias de Prática Clínica como Assunto , Planejamento da Radioterapia Assistida por Computador/normas , Radioterapia Adjuvante , Radioterapia Conformacional/métodos
3.
Int J Radiat Oncol Biol Phys ; 74(5): 1506-12, 2009 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-19395182

RESUMO

PURPOSE: In 2007, Medicare implemented the Physician Quality Reporting Initiative (PQRI), which provides financial incentives to physicians who report their performance on certain quality measures. PQRI measure #74 recommends radiotherapy for patients treated with conservative surgery (CS) for invasive breast cancer. As a first step in evaluating the potential impact of this measure, we assessed baseline use of radiotherapy among women diagnosed with invasive breast cancer before implementation of PQRI. METHODS AND MATERIALS: Using the SEER-Medicare data set, we identified women aged 66-70 diagnosed with invasive breast cancer and treated with CS between 2000 and 2002. Treatment with radiotherapy was determined using SEER and claims data. Multivariate logistic regression tested whether receipt of radiotherapy varied significantly across clinical, pathologic, and treatment covariates. RESULTS: Of 3,674 patients, 94% (3,445) received radiotherapy. In adjusted analysis, the presence of comorbid illness (odds ratio [OR] 1.69; 95% confidence interval [CI], 1.19-2.42) and unmarried marital status were associated with omission of radiotherapy (OR 1.65; 95% CI, 1.22-2.20). In contrast, receipt of chemotherapy was protective against omission of radiotherapy (OR 0.25; 95% CI, 0.16-0.38). Race and geographic region did not correlate with radiotherapy utilization. CONCLUSIONS: Utilization of radiotherapy following CS was high for patients treated before institution of PQRI, suggesting that at most 6% of patients could benefit from measure #74. Further research is needed to determine whether institution of PQRI will affect radiotherapy utilization.


Assuntos
Neoplasias da Mama/radioterapia , Seguro de Serviços Médicos/legislação & jurisprudência , Medicare/legislação & jurisprudência , Idoso , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Feminino , Humanos , Seguro de Serviços Médicos/economia , Modelos Logísticos , Mastectomia Segmentar/legislação & jurisprudência , Medicare/economia , Radioterapia/economia , Radioterapia/estatística & dados numéricos , Programa de SEER , Fatores Socioeconômicos , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA